| MORPHOSYS AG O.N. | 85.72 / +0.28% |
| Date/Time | 10/27 / 17:35 |
| Chg. / Chg.(%) | 0.24 / +0.28% |
| Bid | - |
| Ask | - |
| Open | 85.80 |
| Previous Close | 85.48 |
| High | 86.82 |
| Low | 84.80 |
| Volume [EUR] | 15,773,946.18 |
| Volume [Units] | 184,283 |
| Price fixings | 2486 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 85.72 |  |
184,283 |
| London Inter.. | 85.62 | |
43,183 |
| Cboe Europe .. | 85.66 | |
38,674 |
| Cboe Europe .. | 85.66 | |
19,252 |
| Turquoise | 85.66 | |
14,049 |
| TradeGate | 85.520 | |
9,909 |
| Frankfurt | 85.6000 | |
1,520 |
| gettex | 85.500 | |
240 |
| Düsseldorf | 85.74 | |
71 |
| Stuttgart | 85.540 | |
36 |
| Berlin | 85.04 |  |
30 |
| Hamburg | 85.32 | |
28 |
| Vienna Globa.. | 85.68 | |
0 |
| Hannover | 85.02 | |
0 |
| München | 85.02 | |
0 |
| Lang & Schwa.. | 85.360 | |
|
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 119.3750 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time